Sputnik V

sputnik V

The first registered vaccine for COVID-19

  • Pioneer

  • Approved

  • Immune Boost

  • 91.4% Efficacy Rate

  • NRCM - Ministry of Health Russia

Sputnik V is the world’s 1'st registered vaccine based on a well-studied human adenoviral vector-based platform.

Sputnik V vaccine efficacy against severe cases of coronavirus is 100%

Ranks among top-10 candidate vaccines - World Health Organization’s (WHO) list

Ongoing Sputnik V post-registration clinical trial in Russia involves 40,000 volunteers

Requests for more than 1.2 billion doses of the Sputnik V vaccine

Vaccine Information


  • Product - SPUTNIK V

  • Ministry of Health Russian Federation

  • Two Dose Vaccine

  • Vaccination of Humans to prevent coronavirus infections

  • Pass all human trial

"Safety and efficacy"

After the start of the COVID-19 pandemic Russian researchers extracted a fragment of genetic material from novel coronavirus SARS-COV-2, which codes information about the structure of the spike S-protein, which forms the virus’ “crown” and is responsible for connection with human cells. They inserted it into a familiar adenovirus vector for delivery into a human cell creating the world’s first COVID-19 vaccine. 

In order to ensure lasting immunity Russian scientists came up with a breakthrough idea to use two different types of adenovirus vectors (rAd26 and rAd5) for the first and second vaccination, boosting the effect of the vaccine.

The use of human adenoviruses as vectors is safe because these viruses, which cause the common cold, are not novel and have been around for thousands of years. 

For more Information


One of the largest global vaccine surveys in 11 countries and 1-st in the Middle East and Southeast Asia


frequently asked questions

When will mass production of the Russian vaccine start?

The plan is to ramp up the vaccine production by the end of 2020 in Russia and globally.

Will the vaccine be available in other countries?

Over 30 countries had expressed interest in obtaining the Sputnik V, including UAE, Saudi Arabia, Indonesia, Philippines, Brazil, Mexico, and India.

When will Russia provide full scientific data behind the vaccine?

A scientific article on the results of Phase I-II clinical trials of the vaccine was published in one of the world's most respected medical journals The Lancet in September.

How can I become a volunteer in clinical trials?

The ongoing Sputnik V post-registration clinical trials involve more than 44,000 people in Russia, the United Arab Emirates (UAE), India, Venezuela and Belarus. More countries expressed interest in carrying out clinical trials of Sputnik V. 

When will the vaccine be available?

Russia is launching mass production of Sputnik V using multiple production sites within the country primarily for domestic use. Our partners outside Russia will produce the Sputnik V vaccine for use internationally. 

When will trials begin in my country?

Sputnik V post-registration clinical trials involved over 44,000 people in Russia, the United Arab Emirates (UAE), India, Venezuela and Belarus. More countries expressed interest in carrying out clinical trial of Sputnik V. The start dates for clinical trials will be announced separately for each country. 

What will be the price of Sputnik V vaccine?

The price for individual countries will be defined by factors such as production costs and logistics. In many countries, for example in Russia, vaccination costs will be covered by national health insurance programs. The price will be competitive as making huge profits on the vaccine is not our intention. 

How can I get/purchase the vaccine?

DIIAH Medical Surgical Instruments Trading LLC

Single Business Tower Office 201, Sheikh Zayed RoadBusiness Bay, 

Dubai, United Arab Emirates


(Please fill-up the Requisition Form)